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We first began these studies using the RNaseprotection assay (RPA), which we had earlier used to verify that alternatively spliced forms of the ER were truly present in breast tumors, and were not just artifacts of sensitive polymerase chain reaction (PCR) amplification (Fuqua et al. 1991 (Fuqua et al. , 1992 . RPA performed on RNA from three breast cancer patients who responded to tamoxifen treatment is shown in Figure 3 , left-hand panel. An exon 5 ER-deletion RPA probe was used which generates bands specific for either exon 5, or wild-type mRNA. In these three patients, the RPA showed that exon 5 ER message exceeded that of wild-type ER. However, if a semiquantitative reverse transcriptase (RT)/PCR assay was used to simultaneously measure the relative levels of the variant to wild-type ER (shown in the panel on the right of Fig. 3 
